CN116284375A - pH-independent long-acting type antiserum albumin nano antibody and application thereof - Google Patents
pH-independent long-acting type antiserum albumin nano antibody and application thereof Download PDFInfo
- Publication number
- CN116284375A CN116284375A CN202310346381.8A CN202310346381A CN116284375A CN 116284375 A CN116284375 A CN 116284375A CN 202310346381 A CN202310346381 A CN 202310346381A CN 116284375 A CN116284375 A CN 116284375A
- Authority
- CN
- China
- Prior art keywords
- seq
- nanobody
- serum albumin
- antibody
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000009027 Albumins Human genes 0.000 title claims abstract description 98
- 108010088751 Albumins Proteins 0.000 title claims abstract description 98
- 102000007562 Serum Albumin Human genes 0.000 claims abstract description 48
- 108010071390 Serum Albumin Proteins 0.000 claims abstract description 48
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 30
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 16
- 239000002773 nucleotide Substances 0.000 claims abstract description 3
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 41
- 229920001184 polypeptide Polymers 0.000 claims description 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 40
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 32
- 230000027455 binding Effects 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 31
- 238000009739 binding Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 108091033319 polynucleotide Proteins 0.000 claims description 19
- 102000040430 polynucleotide Human genes 0.000 claims description 19
- 239000002157 polynucleotide Substances 0.000 claims description 19
- 108020001507 fusion proteins Proteins 0.000 claims description 17
- 102000037865 fusion proteins Human genes 0.000 claims description 17
- 230000006870 function Effects 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 30
- 229940079593 drug Drugs 0.000 abstract description 19
- 241000282414 Homo sapiens Species 0.000 abstract description 15
- 241000282567 Macaca fascicularis Species 0.000 abstract description 10
- 238000011161 development Methods 0.000 abstract description 8
- 230000002035 prolonged effect Effects 0.000 abstract description 5
- 238000012827 research and development Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 27
- 238000001514 detection method Methods 0.000 description 20
- 241000700159 Rattus Species 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 102000008100 Human Serum Albumin Human genes 0.000 description 15
- 108091006905 Human Serum Albumin Proteins 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 230000004927 fusion Effects 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 12
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 229940127121 immunoconjugate Drugs 0.000 description 9
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 4
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 101710130607 Valacyclovir hydrolase Proteins 0.000 description 4
- 102100025139 Valacyclovir hydrolase Human genes 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000002073 nanorod Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 2
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000012743 protein tagging Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- -1 trop2 Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- AUXMWYRZQPIXCC-KNIFDHDWSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O AUXMWYRZQPIXCC-KNIFDHDWSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FSWYUDLVKBSHDX-UHFFFAOYSA-N 1,4,5,8-tetrahydronaphthalene Chemical compound C1C=CCC2=C1CC=CC2 FSWYUDLVKBSHDX-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282828 Camelus bactrianus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101150050927 Fcgrt gene Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100033454 Interleukin-17F Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101000928455 Macaca fascicularis Albumin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 108010083912 bleomycin N-acetyltransferase Proteins 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000054663 human IL4R Human genes 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention provides a pH-independent long-acting type anti-serum albumin nano antibody and application thereof. Specifically, the invention provides amino acid sequences of VHH chain framework region FR and complementarity determining region CDR of a pH independent long acting anti-serum albumin nanobody. The invention also provides a nucleotide sequence for encoding the nano antibody. The antiserum albumin nano antibody provided by the invention can be combined with serum albumin of human, mouse, rat and cynomolgus monkey under different pH conditions; and the half life of the protein medicine can be obviously prolonged, and a research and development basis is provided for the development of long-acting protein medicines.
Description
The application is a divisional application of an invention patent application of which the application date is 8/14/2020, the application number is 202010820234.6 and the invention name is 'pH-independent long-acting anti-serum albumin nano antibody and application'.
Technical Field
The invention relates to the technical field of biomedicine or biopharmaceuticals, in particular to a pH-independent long-acting type anti-serum albumin nano antibody and application thereof.
Background
As an important parameter of pharmacokinetics, the half-life of an antibody comprehensively represents the process of absorption and distribution of the antibody in vivo. The half-life period can be improved effectively, the drug effect of the antibody can be improved, the dosage and the frequency of administration can be reduced, the possible side effect can be reduced, and the treatment burden of patients can be reduced. How to change the half-life of antibody drugs has been an important research direction in the field of antibody engineering. Various factors affecting the drug half-life of antibodies, including: molecular weight, fcRn binding, isoelectric point, glycosylation, target-mediated clearance, anti-drug antibodies, and the like. Current strategies for achieving half-life extension of antibody drugs include glycosylation engineering, pegylation, albumin fusion, transferrin fusion, fc fusion, inert protein fusion, negative electric protein fusion, and the like.
Human serum albumin is the most abundant soluble protein in human plasma, and is also a carrier for many endogenous factors and exogenous drugs. Human serum albumin consists of 585 amino acids and has a relative molecular mass of about 66.5kDa. Because the human serum albumin is not easy to penetrate kidney glomeruli under normal conditions, the half-life period of the human serum albumin in blood plasma is long (can reach 14-20 days and is about 19 days on average), and the human serum albumin has no enzymatic and immunological activities, is safe and nontoxic, has good biocompatibility and extremely wide in-vivo distribution, and is an ideal drug carrier. Various long-acting techniques of human serum albumin-based drugs have been widely used and developed, and currently mainly include the construction of human serum albumin fusion proteins, the coupling with human serum albumin through covalent chemical bonds, the reversible binding with human serum albumin through non-covalent bonds, and the like.
Nanobody (Nb), a heavy chain single domain antibody VHH (variable domain of heavychain of heavy-chain antibody) -heavy chain antibodies (hcabs) in which naturally deleted light chains are present in the camelid. The single domain antibody consisting of only one heavy chain variable region obtained by cloning the variable region thereof is the smallest unit of the stable, bindable antigen having a complete function that is currently available. The nano antibody has the characteristics of high stability, good water solubility, simple humanization, high targeting property, strong penetrability and the like, and plays an unexpectedly large function in immune experiments, diagnosis and treatment. Ablynx corporation, the army corporation in the world nanobody field, is the earliest enterprise to use nanobodies for therapeutic antibody development, which already has more than 45 proprietary and cooperative nanobodies, and among them, there are various products that are fusion proteins constructed with anti-human serum albumin as a long-acting factor, such as products targeting IL-6R, TNF-alpha, RANKL or IL-17A/IL17F, and the like.
Although there are several patent documents in the prior art reporting nanobodies against human serum albumin, there are some disadvantages in application of the existing nanobodies, and there is a need in the art to develop new nanobodies with better functions.
Disclosure of Invention
The invention aims to provide a pH-independent long-acting type anti-serum albumin nano antibody and application thereof.
Specifically, the invention provides 4 nano antibodies which specifically bind to serum albumin, and simultaneously provides a coding sequence, a preparation method and application of the nano antibodies.
In a first aspect of the invention there is provided an anti-serum albumin nanobody which is capable of specifically binding to serum albumin and the complementarity determining region CDRs of the VHH chain of the nanobody are one or more selected from the group consisting of:
(1) CDR1 shown in SEQ ID NO. 1, CDR2 shown in SEQ ID NO. 2, and CDR3 shown in SEQ ID NO. 3;
(2) CDR1 shown in SEQ ID NO. 10, CDR2 shown in SEQ ID NO. 11, and CDR3 shown in SEQ ID NO. 12;
(3) CDR1 shown in SEQ ID NO. 19, CDR2 shown in SEQ ID NO. 20, and CDR3 shown in SEQ ID NO. 21; and
(4) CDR1 shown in SEQ ID NO. 28, CDR2 shown in SEQ ID NO. 29, and CDR3 shown in SEQ ID NO. 30.
In another preferred embodiment, the anti-serum albumin nanobody is a pH-independent long-acting anti-serum albumin nanobody.
In another preferred embodiment, the anti-serum albumin nanobody comprises an immunoglobulin single variable domain that specifically binds serum albumin.
In another preferred embodiment, the anti-serum albumin nanobody comprises two or more immunoglobulin single variable domains that specifically bind serum albumin.
In another preferred embodiment, the immunoglobulin single variable domain comprises a CDR1, CDR2, and CDR3 selected from the group consisting of:
(1) CDR1 shown in SEQ ID NO. 1, CDR2 shown in SEQ ID NO. 2, and CDR3 shown in SEQ ID NO. 3;
(2) CDR1 shown in SEQ ID NO. 10, CDR2 shown in SEQ ID NO. 11, and CDR3 shown in SEQ ID NO. 12;
(3) CDR1 shown in SEQ ID NO. 19, CDR2 shown in SEQ ID NO. 20, and CDR3 shown in SEQ ID NO. 21; and
(4) CDR1 shown in SEQ ID NO. 28, CDR2 shown in SEQ ID NO. 29, and CDR3 shown in SEQ ID NO. 30.
In another preferred embodiment, any of the above amino acid sequences further comprises a derivative sequence which is optionally added, deleted, modified and/or substituted with at least one (e.g., 1-3, preferably 1-2, more preferably 1) amino acid and which retains the ability to specifically bind serum albumin in a pH independent manner.
In another preferred embodiment, the CDR1, CDR2 and CDR3 are separated by the framework regions FR1, FR2, FR3 and FR4 of the VHH chain.
In another preferred embodiment, the serum albumin is human or non-human mammalian serum albumin.
In another preferred embodiment, the serum albumin is human, mouse, rat or cynomolgus serum albumin.
In another preferred embodiment, the anti-serum albumin nanobody has a pH-independent property.
In another preferred embodiment, the anti-serum albumin nanobody is capable of binding serum albumin at different pH conditions.
In another preferred embodiment, the anti-serum albumin nanobody is capable of binding serum albumin at a pH of 3.0-10.0, preferably pH4.0-9.0, more preferably pH 5.0-8.0.
In another preferred embodiment, the monoclonal antibody has a binding activity to serum albumin of A1 at about pH 7.4 or more (preferably 7.8 or more, more preferably 8.0 or more; and pH 8.5 or less); the monoclonal antibody has a binding activity to serum albumin of A2 at a pH of about 5.0 or less (preferably 4.8 or less, more preferably 4.5 or less; and a pH of 4.0 or more); then 0.5.ltoreq.A1/A2.ltoreq.2, preferably 0.7.ltoreq.A1/A2.ltoreq.1.5, more preferably 0.8.ltoreq.A1/A2.ltoreq.1.2.
In another preferred embodiment, the framework region of the nanobody comprises FRl, FR2, FR3 and FR4 selected from the group consisting of:
(1) FR1 shown in SEQ ID NO. 4, FR2 shown in SEQ ID NO. 5, FR3 shown in SEQ ID NO. 6 and FR4 shown in SEQ ID NO. 7;
(2) FR1 shown in SEQ ID NO. 13, FR2 shown in SEQ ID NO. 14, FR3 shown in SEQ ID NO. 15 and FR4 shown in SEQ ID NO. 16;
(3) FR1 shown in SEQ ID NO. 22, FR2 shown in SEQ ID NO. 23, FR3 shown in SEQ ID NO. 24 and FR4 shown in SEQ ID NO. 25;
(4) FR1 shown in SEQ ID NO. 31, FR2 shown in SEQ ID NO. 32, FR3 shown in SEQ ID NO. 33 and FR4 shown in SEQ ID NO. 34;
(5) FR1 shown in SEQ ID NO. 37, FR2 shown in SEQ ID NO. 38, FR3 shown in SEQ ID NO. 39 and FR4 shown in SEQ ID NO. 40;
(6) FR1 shown in SEQ ID NO. 43, FR2 shown in SEQ ID NO. 44, FR3 shown in SEQ ID NO. 45 and FR4 shown in SEQ ID NO. 46;
(7) FR1 shown in SEQ ID NO. 49, FR2 shown in SEQ ID NO. 50, FR3 shown in SEQ ID NO. 51 and FR4 shown in SEQ ID NO. 52; and
(8) FR1 shown in SEQ ID NO. 55, FR2 shown in SEQ ID NO. 56, FR3 shown in SEQ ID NO. 57 and FR4 shown in SEQ ID NO. 58.
In another preferred embodiment, the amino acid sequence of the VHH chain in the antibody is selected from the group consisting of: SEQ ID NO. 8, SEQ ID NO. 17, SEQ ID NO. 26, SEQ ID NO. 35, SEQ ID NO. 41, SEQ ID NO. 47, SEQ ID NO. 53, SEQ ID NO. 59, or a combination thereof.
In another preferred embodiment, the amino acid sequence of the VHH chain in the antibody is selected from the group consisting of: SEQ ID NO. 41, SEQ ID NO. 47, SEQ ID NO. 53, SEQ ID NO. 59, or a combination thereof.
In another preferred embodiment, the nanobody comprises a humanized antibody, a camelid antibody, or a chimeric antibody.
In another preferred embodiment, the serum albumin-specific nanobody of the invention also encompasses an anti-serum albumin antibody molecule capable of binding to human serum albumin with a VHH consisting of the amino acid sequence of any one of SEQ ID NO:8, SEQ ID NO:17, SEQ ID NO:26, SEQ ID NO:35, SEQ ID NO:41, SEQ ID NO:47, SEQ ID NO:53 or SEQ ID NO: 59.
In a second aspect of the invention there is provided an anti-serum albumin antibody comprising one or more VHH chains of a nanobody according to the first aspect of the invention.
In another preferred example, the anti-serum albumin antibody may be a monomer, a bivalent antibody, and/or a multivalent antibody.
In a third aspect of the invention, there is provided an isolated polynucleotide encoding an antisera albumin nanobody according to the first aspect of the invention or an antisera albumin antibody according to the second aspect of the invention.
In another preferred embodiment, the polynucleotides are in a combinatorial form.
In another preferred embodiment, the sequence of the polynucleotide is selected from the group consisting of: SEQ ID NO. 9, SEQ ID NO. 18, SEQ ID NO. 27, SEQ ID NO. 36, SEQ ID NO. 42, SEQ ID NO. 48, SEQ ID NO. 54, SEQ ID NO. 60, or a combination thereof.
In another preferred embodiment, the invention relates to a nucleic acid molecule encoding an anti-serum albumin nanobody of the invention. The nucleic acid of the invention may be RNA, DNA or cDNA.
In a fourth aspect of the invention there is provided an expression vector expressing a polynucleotide of the third aspect of the invention.
In another preferred embodiment, the expression vector is selected from the group consisting of: DNA, RNA, viral vectors, plasmids, transposons, other gene transfer systems, or combinations thereof.
In another preferred embodiment, the viral vector comprises a lentiviral vector, an adenoviral vector, an AAV viral vector, a retroviral vector, or a combination thereof.
In a fifth aspect of the invention there is provided a host cell comprising an expression vector according to the fourth aspect of the invention, or having integrated into its genome a polynucleotide according to the third aspect of the invention.
In another preferred embodiment, the host cell comprises a prokaryotic cell or a eukaryotic cell.
In another preferred embodiment, the host cell is selected from the group consisting of: coli, yeast cells, mammalian cells.
In a sixth aspect of the present invention, there is provided a method of producing an anti-serum albumin nanobody comprising the steps of:
(a) Culturing the host cell of the fifth aspect of the invention under conditions suitable for nanobody production, thereby obtaining a culture comprising said anti-serum albumin nanobody; and
(b) Isolating or recovering said anti-serum albumin nanobodies from said culture; optionally, a plurality of metal sheets
(c) Purifying and/or modifying the antisera albumin nanobody obtained in step (b).
In another preferred embodiment, the anti-serum albumin nanobody has an amino acid sequence as shown in SEQ ID NO. 8, SEQ ID NO. 17, SEQ ID NO. 26, SEQ ID NO. 35, SEQ ID NO. 41, SEQ ID NO. 47, SEQ ID NO. 53 or SEQ ID NO. 59.
In a seventh aspect of the invention, there is provided an immunoconjugate comprising:
(a) An anti-serum albumin nanobody according to the first aspect of the invention, or an anti-serum albumin antibody according to the second aspect of the invention; and
(b) A coupling moiety selected from the group consisting of: a detectable label, drug, cytokine, radionuclide, enzyme, gold nanoparticle/nanorod, nanomagnetic particle, viral coat protein, or VLP, or a combination thereof.
In another preferred embodiment, components (a) and (b) are operably linked.
In another preferred embodiment, the coupling moiety is a chemical label or a biomarker.
In another preferred embodiment, the chemical label is an isotope, an immunotoxin, and/or a chemical drug.
In another preferred embodiment, the biomarker is biotin, avidin, or an enzyme label.
In another preferred embodiment, the radionuclide comprises:
(i) A diagnostic isotope selected from the group consisting of: tc-99m, ga-68, F-18, I-123, I-125, I-131, in-111, ga-67, cu-64, zr-89, C-11, lu-177, re-188, or a combination thereof; and/or
(ii) A therapeutic isotope selected from the group consisting of: lu-177, Y-90, ac-225, as-211, bi-212, bi-213, cs-137, cr-51, co-60, dy-165, er-169, fm-255, au-198, ho-166, I-125, I-131, ir-192, fe-59, pb-212, mo-99, pd-103, P-32, K-42, re-186, re-188, sm-153, ra223, ru-106, na24, sr89, tb-149, th-227, xe-133, yb-169, yb-177, or combinations thereof.
In another preferred embodiment, the coupling moiety is a detectable label.
In another preferred embodiment, the coupling moiety is selected from the group consisting of: fluorescent or luminescent labels, radioactive labels, MRI (magnetic resonance imaging) or CT (computed tomography) contrast agents, or enzymes capable of producing a detectable product, radionuclides, biotoxins, cytokines (e.g., IL-2, etc.), antibodies, antibody Fc fragments, antibody scFv fragments, gold nanoparticles/nanorods, viral particles, liposomes, nanomagnetic particles, prodrug-activating enzymes (e.g., DT-diaphorase (DTD) or biphenyl hydrolase-like proteins (BPHL)) or any form of nanoparticle.
In an eighth aspect of the invention, there is provided a conjugate comprising:
(a) An anti-serum albumin nanobody according to the first aspect of the invention, or an anti-serum albumin antibody according to the second aspect of the invention; and operatively connected to
(b) A modification marker selected from the group consisting of: chemical markers and biological markers.
In another preferred embodiment, the chemical label is an isotope, an immunotoxin, and/or a chemical drug.
In another preferred embodiment, the biomarker is biotin, avidin, or an enzyme label.
In a ninth aspect of the invention, there is provided a multispecific antibody comprising: the anti-serum albumin nanobody according to the first aspect of the invention or the anti-serum albumin antibody according to the second aspect of the invention.
In another preferred embodiment, the multispecific antibody further comprises a second antigen-binding region that targets a target selected from the group consisting of: IL-4R, IL-4Rα, TNF- α, VEGF, PD-1, PD-L1, 4-1BB, CD47, TIM3, CTLA4, IL-17A, CD, CD22, CD38, IL-5, TSLP, BCMA, GLP-1, trop2, TIGIT, or combinations thereof.
In another preferred embodiment, the second antigen binding region is a nanobody.
In another preferred embodiment, the multispecific antibody comprises one or more second antigen-binding regions.
In another preferred embodiment, the multispecific antibody further comprises an Fc fragment of an antibody.
In another preferred embodiment, the multispecific antibody is a bispecific antibody that targets serum albumin and IL 4R.
In another preferred embodiment, the multispecific antibody comprises one anti-serum albumin nanobody and two anti-IL 4R nanobodies.
In another preferred embodiment, the multispecific antibody is a trivalent antibody.
In another preferred embodiment, the bispecific antibody has the structure of formula I:
I-I-B formula I
Wherein,,
"-" is a peptide bond;
i is an anti-IL 4R nanobody;
b is an antiserum albumin nanobody according to the first aspect of the invention.
In a tenth aspect of the present invention, there is provided a fusion protein comprising:
(i) An anti-serum albumin nanobody according to the first aspect of the invention, or an anti-serum albumin antibody according to the second aspect of the invention;
(ii) Optionally a polypeptide molecule or fragment having therapeutic functions.
In another preferred embodiment, the polypeptide molecule or fragment having therapeutic function includes, but is not limited to: a polypeptide molecule or fragment that targets IL-4R, IL-4 ra, TNF-a, VEGF, PD-1, PD-L1, 4-1BB, CD47, TIM3, CTLA4, IL-17A, CD19, CD22, CD38, IL-5, TSLP, BCMA, GLP-1, trop2, or TIGIT.
In another preferred embodiment, the polypeptide molecule or fragment having therapeutic function includes, but is not limited to: insulin, IL-2, interferon, calcitonin, GHRH peptide, intestinal peptide analog, albumin, antibody fragment, cytokine.
In another preferred embodiment, the polypeptide molecule or fragment having therapeutic function comprises a single chain antibody (scFv), a diabody, a monoclonal antibody, or a chimeric antibody.
In another preferred embodiment, the fusion protein further comprises a tag sequence that facilitates expression and/or purification.
In another preferred embodiment, the tag sequence is selected from the group consisting of: 6His tag, GGGS sequence, FLAG tag.
In another preferred embodiment, the fusion protein comprises a bispecific antibody or a chimeric antibody.
In an eleventh aspect of the present invention, there is provided a pharmaceutical composition comprising:
(i) An anti-serum albumin nanobody according to the first aspect of the invention, an anti-serum albumin antibody according to the second aspect of the invention, an immunoconjugate according to the seventh aspect of the invention, a conjugate according to the eighth aspect of the invention, a multispecific antibody according to the ninth aspect of the invention or a fusion protein according to the tenth aspect of the invention;
(ii) A pharmaceutically acceptable carrier.
In another preferred embodiment, the pharmaceutical composition further comprises other biologically active substances, such as a medicament for treating tumors.
In a twelfth aspect of the invention there is provided the use of an active ingredient selected from the group consisting of: the antisera albumin nanobody according to the first aspect of the invention, the antisera albumin antibody according to the second aspect of the invention, the immunoconjugate according to the seventh aspect of the invention, the conjugate according to the eighth aspect of the invention, the multispecific antibody according to the ninth aspect of the invention, the fusion protein according to the tenth aspect of the invention, or a combination thereof, is used for the preparation of a long-acting protein medicament.
In a thirteenth aspect of the invention there is provided the use of an anti-serum albumin nanobody according to the first aspect of the invention, an anti-serum albumin antibody according to the second aspect of the invention, or an immunoconjugate according to the seventh aspect of the invention: (a) Reagents, assay plates or kits for preparing a reagent for detecting serum albumin; (b) For the preparation of a medicament (long acting protein drug) that binds serum albumin.
In another preferred embodiment, the reagent is a diagnostic reagent.
In another preferred embodiment, the reagent is used to detect serum albumin or a fragment thereof in a sample.
In another preferred embodiment, the agent comprises an immunoconjugate according to the seventh aspect of the invention, a conjugate according to the eighth aspect of the invention, a multispecific antibody according to the ninth aspect of the invention, or a fusion protein according to the tenth aspect of the invention.
In a fourteenth aspect of the present invention there is provided an immunoadsorbent material for purifying serum albumin, wherein the immunoadsorbent material comprises an anti-serum albumin nanobody as described in the first or second aspect, a VHH chain of an anti-serum albumin nanobody as described in the first or second aspect of the invention.
In another preferred embodiment, the immunoadsorbent material further comprises a carrier.
In another preferred embodiment, the carrier includes, but is not limited to: magnetic beads, agarose gel, silica gel microspheres, and porous materials.
In a fifteenth aspect of the present invention, there is provided a method of detecting serum albumin or a fragment thereof in a sample in vitro, the method comprising the steps of:
(1) Contacting the sample in vitro with an anti-serum albumin nanobody according to the first aspect of the invention, an anti-serum albumin antibody according to the second aspect of the invention, or an immunoconjugate according to the seventh aspect of the invention;
(2) Detecting whether an antigen-antibody complex is formed, wherein the formation of a complex indicates the presence of serum albumin or a fragment thereof in the sample.
In another preferred embodiment, the detection comprises diagnostic or non-diagnostic.
In a sixteenth aspect of the present invention, there is provided a method for producing a recombinant polypeptide, the method comprising:
(a) Culturing a host cell according to the fifth aspect of the invention under conditions suitable for expression;
(b) Isolating from the culture a recombinant polypeptide comprising an anti-serum albumin nanobody according to the first aspect of the invention, an anti-serum albumin antibody according to the second aspect of the invention, a multispecific antibody according to the ninth aspect of the invention, and a fusion protein according to the tenth aspect of the invention.
It is understood that within the scope of the present invention, the above-described technical features of the present invention and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. And are limited to a space, and are not described in detail herein.
Drawings
FIG. 1A shows the binding activity of albumin nanobody Nb1-15 to human, mouse, rat, cynomolgus serum albumin at different pH conditions.
FIG. 1B shows the binding activity of albumin nanobody Nb1-60 to human, mouse, rat, cynomolgus serum albumin at different pH conditions.
FIG. 1C shows the binding activity of albumin nanobody Nb1-83 to human, mouse, rat, cynomolgus serum albumin at different pH conditions.
FIG. 1D shows the binding activity of albumin nanobody Nb3-24 to human, mouse, rat, cynomolgus serum albumin at different pH conditions.
FIG. 2A shows the binding activity of IL4R nanobody fusion humanized albumin nanobody HuNb1-15 to human, mouse, rat, cynomolgus monkey serum albumin under different pH conditions.
FIG. 2B shows the binding activity of IL4R nanobody to human, mouse, rat, cynomolgus serum albumin at different pH conditions after fusion of humanized albumin nanobody HuNb 1-60.
FIG. 2C shows the binding activity of IL4R nanobody to human, mouse, rat, cynomolgus serum albumin at different pH conditions after fusion of humanized albumin nanobody HuNb 1-83.
FIG. 2D shows the binding activity of IL4R nanobody to human, mouse, rat, cynomolgus serum albumin at different pH conditions after fusion of humanized albumin nanobody HuNb 3-24.
FIG. 3 shows the half-life detection results of IL4R-HSA trivalent antibodies in mice.
FIG. 4 shows the half-life detection results of IL4R-HSA trivalent antibodies in rats.
FIG. 5 shows the half-life detection results of IL4R-HSA trivalent antibodies in cynomolgus monkeys.
Detailed Description
Through extensive and intensive research, the inventor successfully obtains a group of antiserum albumin nanobodies through a large number of screening, and experimental results show that the 4 antiserum albumin nanobodies obtained by the invention can be effectively combined with serum albumin. The present invention has been completed on the basis of this finding.
Specifically, the invention utilizes human serum albumin extracellular antigen protein to immunize camels, and obtains a high-quality immune nanobody gene library. And coupling serum albumin molecules on an ELISA plate, displaying the correct space structure of serum albumin, and screening an immune nanobody gene library (camel heavy chain antibody phage display gene library) by using phage display technology by using the antigen in the form, so as to obtain serum albumin specific nanobody genes.
As used herein, the terms "nanobody of the invention", "nanobody of the antisera albumin of the invention", are used interchangeably and refer to nanobodies that specifically recognize and bind to serum albumin (including human serum albumin). Particularly preferred are nanobodies of the amino acid sequence of the VHH chain as shown in SEQ ID NO. 41, SEQ ID NO. 47, SEQ ID NO. 53 or SEQ ID NO. 59.
As used herein, the term "antibody" or "immunoglobulin" is an iso-tetralin protein of about 150000 daltons, consisting of two identical light chains (L) and two identical heavy chains (H), having identical structural features. Each light chain is linked to the heavy chain by a covalent disulfide bond, while the number of disulfide bonds varies between heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bonds. Each heavy chain has a variable region (VH) at one end followed by a plurality of constant regions. One end of each light chain is provided with a variable region (VL) and the other end is provided with a constant region; the constant region of the light chain is opposite the first constant region of the heavy chain and the variable region of the light chain is opposite the variable region of the heavy chain. Specific amino acid residues form an interface between the variable regions of the light and heavy chains.
As used herein, the terms "single domain antibody (single domain antibody, sdAb, or VHH)", "nanobody" (nanobody) have the same meaning, referring to the variable region of a cloned antibody heavy chain, to construct a nanobody consisting of only one heavy chain variable region, which is the smallest antigen-binding fragment with complete function. Typically, the naturally deleted light and heavy chain constant region 1 (CH 1) antibodies are obtained first, and then the variable region of the heavy chain of the antibody is cloned to construct nanobodies (VHHs) consisting of only one heavy chain variable region.
Nanobody/single domain antibody (Nanobody) is a novel small molecule antibody fragment obtained by cloning a heavy chain variable region (VHH) of a camelid natural heavy chain antibody. Nanobody (Nb) has excellent biological characteristics, has a molecular weight of 12-15kDa, is one tenth of that of an intact antibody, has good tissue penetrability, high specificity and good water solubility. Because of the special structural property, the antibody has the advantages of the traditional antibody and the small molecular medicine, almost perfectly overcomes the defects of long development period, lower stability, harsh preservation condition and the like of the traditional antibody, gradually becomes an emerging force in the treatment of the new generation antibody, and shows wide application prospect in immunodiagnosis and treatment.
As used herein, the term "variable" means that certain portions of the variable regions in an antibody differ in sequence, which results in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the antibody variable region. It is concentrated in three fragments in the light and heavy chain variable regions called Complementarity Determining Regions (CDRs) or hypervariable regions. The more conserved parts of the variable region are called Framework Regions (FR). The variable regions of the natural heavy and light chains each comprise four FR regions, which are generally in a β -sheet configuration, connected by three CDRs forming the connecting loops, which in some cases may form part of the β -sheet structure. The CDRs in each chain are held closely together by the FR regions and together with the CDRs of the other chain form the antigen binding site of the antibody (see Kabat et al, NIH publication No.91-3242, vol. I, pp. 647-669 (1991)). The constant regions are not directly involved in binding of the antibody to the antigen, but they exhibit different effector functions, such as participation in antibody-dependent cytotoxicity of the antibody.
Immunoconjugates and fusion expression products include, as known to those of skill in the art: conjugates of drugs, toxins, cytokines (cytokines), radionuclides, enzymes and other diagnostic or therapeutic molecules in combination with antibodies or fragments thereof of the present invention. The invention also includes cell surface markers or antigens that bind to the anti-serum albumin antibodies or fragments thereof.
As used herein, the terms "heavy chain variable region" and "V H "interchangeably used.
As used herein, the term "variable region" is used interchangeably with "complementarity determining region (complementarity determining region, CDR)".
In a preferred embodiment of the invention, the heavy chain variable region of the antibody comprises three complementarity determining regions CDR1, CDR2, and CDR3.
In a preferred embodiment of the invention, the heavy chain of the antibody comprises the heavy chain variable region and the heavy chain constant region described above.
In the present invention, the terms "antibody of the invention", "protein of the invention", or "polypeptide of the invention" are used interchangeably to refer to a polypeptide that specifically binds serum albumin, such as a protein or polypeptide having a heavy chain variable region. They may or may not contain an initiating methionine.
The invention also provides other proteins or fusion expression products having the antibodies of the invention. In particular, the invention includes any protein or protein conjugate and fusion expression product (i.e., immunoconjugate and fusion expression product) having a heavy chain comprising a variable region, provided that the variable region is identical or at least 90% homologous, preferably at least 95% homologous, to the heavy chain variable region of an antibody of the invention.
In general, the antigen binding properties of antibodies can be described by 3 specific regions located in the variable region of the heavy chain, called variable regions (CDRs), which are separated into 4 Framework Regions (FRs), the amino acid sequences of which 4 FRs are relatively conserved and do not directly participate in the binding reaction. These CDRs form a loop structure, the β -sheets formed by the FR therebetween are spatially close to each other, and the CDRs on the heavy chain and the CDRs on the corresponding light chain constitute the antigen binding site of the antibody. It is possible to determine which amino acids constitute the FR or CDR regions by comparing the amino acid sequences of the same type of antibody.
The variable regions of the heavy chains of the antibodies of the invention are of particular interest because they are involved, at least in part, in binding to antigens. Thus, the invention includes those molecules having antibody heavy chain variable regions with CDRs, so long as the CDRs are 90% or more (preferably 95% or more, most preferably 98% or more) homologous to the CDRs identified herein.
The invention includes not only whole antibodies but also fragments of antibodies having immunological activity or fusion proteins of antibodies with other sequences. Thus, the invention also includes fragments, derivatives and analogues of said antibodies.
As used herein, the terms "fragment," "derivative," and "analog" refer to polypeptides that retain substantially the same biological function or activity of an antibody of the invention. The polypeptide fragment, derivative or analogue of the invention may be (i) a polypeptide having one or more conserved or non-conserved amino acid residues, preferably conserved amino acid residues, substituted, which may or may not be encoded by the genetic code, or (ii) a polypeptide having a substituent in one or more amino acid residues, or (iii) a polypeptide formed by fusion of a mature polypeptide with another compound, such as a compound that extends the half-life of the polypeptide, for example polyethylene glycol, or (iv) a polypeptide formed by fusion of an additional amino acid sequence to the polypeptide sequence, such as a leader or secretory sequence or a sequence used to purify the polypeptide or a proprotein sequence, or a fusion protein with a 6His tag. Such fragments, derivatives and analogs are within the purview of one skilled in the art and would be well known in light of the teachings herein.
The antibody of the present invention refers to a polypeptide having serum albumin binding activity, comprising the above-mentioned CDR regions. The term also includes variants of polypeptides comprising the above-described CDR regions that have the same function as the antibodies of the invention. These variants include (but are not limited to): deletion, insertion and/or substitution of one or more (usually 1 to 50, preferably 1 to 30, more preferably 1 to 20, most preferably 1 to 10) amino acids, and addition of one or several (usually 20 or less, preferably 10 or less, more preferably 5 or less) amino acids at the C-terminal and/or N-terminal end. For example, in the art, substitution with amino acids of similar or similar properties does not generally alter the function of the protein. As another example, the addition of one or more amino acids at the C-terminus and/or N-terminus typically does not alter the function of the protein. The term also includes active fragments and active derivatives of the antibodies of the invention.
The variant forms of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA which hybridizes under high or low stringency conditions with the encoding DNA of an antibody of the invention, and polypeptides or proteins obtained using antisera raised against an antibody of the invention.
The invention also provides other polypeptides, such as fusion proteins comprising nanobodies or fragments thereof. In addition to nearly full length polypeptides, the invention also includes fragments of the nanobodies of the invention. Typically, the fragment has at least about 50 contiguous amino acids, preferably at least about 50 contiguous amino acids, more preferably at least about 80 contiguous amino acids, and most preferably at least about 100 contiguous amino acids of the antibody of the invention.
In the present invention, a "conservative variant of an antibody of the present invention" refers to a polypeptide in which at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acids are replaced by amino acids of similar or similar nature, as compared to the amino acid sequence of the antibody of the present invention. These conservatively mutated polypeptides are preferably produced by amino acid substitution according to Table 1.
TABLE 1
Initial residues | Representative substitution | Preferred substitution |
Ala(A) | Val;Leu;Ile | Val |
Arg(R) | Lys;Gln;Asn | Lys |
Asn(N) | Gln;His;Lys;Arg | Gln |
Asp(D) | Glu | Glu |
Cys(C) | Ser | Ser |
Gln(Q) | Asn | Asn |
Glu(E) | Asp | Asp |
Gly(G) | Pro;Ala | Ala |
His(H) | Asn;Gln;Lys;Arg | Arg |
Ile(I) | Leu;Val;Met;Ala;Phe | Leu |
Leu(L) | Ile;Val;Met;Ala;Phe | Ile |
Lys(K) | Arg;Gln;Asn | Arg |
Met(M) | Leu;Phe;Ile | Leu |
Phe(F) | Leu;Val;Ile;Ala;Tyr | Leu |
Pro(P) | Ala | Ala |
Ser(S) | Thr | Thr |
Thr(T) | Ser | Ser |
Trp(W) | Tyr;Phe | Tyr |
Tyr(Y) | Trp;Phe;Thr;Ser | Phe |
Val(V) | Ile;Leu;Met;Phe;Ala | Leu |
The invention also provides polynucleotide molecules encoding the antibodies or fragments thereof or fusion proteins thereof. The polynucleotides of the invention may be in the form of DNA or RNA. DNA forms include cDNA, genomic DNA, or synthetic DNA. The DNA may be single-stranded or double-stranded. The DNA may be a coding strand or a non-coding strand.
Polynucleotides encoding the mature polypeptides of the invention include: a coding sequence encoding only the mature polypeptide; a coding sequence for a mature polypeptide and various additional coding sequences; the coding sequence (and optionally additional coding sequences) of the mature polypeptide, and non-coding sequences.
The term "polynucleotide encoding a polypeptide" may include polynucleotides encoding the polypeptide, or may include additional coding and/or non-coding sequences.
The invention also relates to polynucleotides which hybridize to the sequences described above and which have at least 50%, preferably at least 70%, more preferably at least 80% identity between the two sequences. The present invention relates in particular to polynucleotides which hybridize under stringent conditions to the polynucleotides of the invention. In the present invention, "stringent conditions" means: (1) Hybridization and elution at lower ionic strength and higher temperature, e.g., 0.2 XSSC, 0.1% SDS,60 ℃; or (2) adding denaturing agents such as 50% (v/v) formamide, 0.1% calf serum/0.1% Ficoll,42℃and the like during hybridization; or (3) hybridization only occurs when the identity between the two sequences is at least 90% or more, more preferably 95% or more. Furthermore, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.
The full-length nucleotide sequence of the antibody of the present invention or a fragment thereof can be generally obtained by a PCR amplification method, a recombinant method or an artificial synthesis method. One possible approach is to synthesize the sequences of interest by synthetic means, in particular with short fragment lengths. In general, fragments of very long sequences are obtained by first synthesizing a plurality of small fragments and then ligating them. In addition, the heavy chain coding sequence and the expression tag (e.g., 6 His) may be fused together to form a fusion protein.
Once the relevant sequences are obtained, recombinant methods can be used to obtain the relevant sequences in large quantities. This is usually done by cloning it into a vector, transferring it into a cell, and isolating the relevant sequence from the propagated host cell by conventional methods. The biomolecules (nucleic acids, proteins, etc.) to which the present invention relates include biomolecules that exist in an isolated form.
At present, it is already possible to obtain the DNA sequences encoding the proteins of the invention (or fragments or derivatives thereof) entirely by chemical synthesis. The DNA sequence can then be introduced into a variety of existing DNA molecules (or vectors, for example) and cells known in the art. In addition, mutations can be introduced into the protein sequences of the invention by chemical synthesis.
The invention also relates to vectors comprising the above-described suitable DNA sequences and suitable promoter or control sequences. These vectors may be used to transform an appropriate host cell to enable expression of the protein.
The host cell may be a prokaryotic cell, such as a bacterial cell; or lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Representative examples are: coli, streptomyces; bacterial cells of salmonella typhimurium; fungal cells such as yeast; insect cells of Drosophila S2 or Sf 9; animal cells of CHO, COS7, 293 cells, and the like.
Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art. When the host is a prokaryote such as E.coli, competent cells, which can take up DNA, can be obtained after the exponential growth phase and then treated with CaCl 2 The process is carried out using procedures well known in the art. Another approach is to use MgCl 2 . Transformation can also be performed by electroporation, if desired. When the host is eukaryotic, the following DNA transfection methods may be used: calcium phosphate co-precipitation, conventional mechanical methods such as microinjection, electroporation, liposome encapsulation, and the like.
The transformant obtained can be cultured by a conventional method to express the polypeptide encoded by the gene of the present invention. The medium used in the culture may be selected from various conventional media depending on the host cell used. The culture is carried out under conditions suitable for the growth of the host cell. After the host cells have grown to the appropriate cell density, the selected promoters are induced by suitable means (e.g., temperature switching or chemical induction) and the cells are cultured for an additional period of time.
The recombinant polypeptide in the above method may be expressed in a cell, or on a cell membrane, or secreted outside the cell. If desired, the recombinant proteins can be isolated and purified by various separation methods using their physical, chemical and other properties. Such methods are well known to those skilled in the art. Examples of such methods include, but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (salting-out method), centrifugation, osmotic sterilization, super-treatment, super-centrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high Performance Liquid Chromatography (HPLC), and other various liquid chromatography techniques and combinations of these methods.
The antibodies of the invention may be used alone or in combination or coupling with a detectable label (for diagnostic purposes), a therapeutic agent, a PK (protein kinase) modifying moiety, or a combination of any of the above.
Detectable markers for diagnostic purposes include, but are not limited to: fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (electronic computer tomography) contrast agents, or enzymes capable of producing a detectable product.
Therapeutic agents that may be conjugated or coupled to an antibody of the invention include, but are not limited to: 1. a radionuclide; 2. biological toxicity; 3. cytokines such as IL-2, etc.; 4. gold nanoparticles/nanorods; 5. a viral particle; 6. a liposome; 7. nano magnetic particles; 8. drug-activated enzymes (e.g., DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL)); 9. therapeutic agents (e.g., cisplatin) or any form of nanoparticle, etc.
Pharmaceutical composition
The invention also provides a composition. Preferably, the composition is a pharmaceutical composition comprising an antibody or active fragment thereof or fusion protein thereof as described above, and a pharmaceutically acceptable carrier or excipient, and optionally other biologically active substances. Typically, these materials are formulated in a nontoxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is typically about 5 to 8, preferably about 6 to 8, although the pH may vary depending on the nature of the material being formulated and the condition being treated. The formulated pharmaceutical compositions may be administered by conventional routes including, but not limited to: intraperitoneal, intravenous, or topical administration.
The pharmaceutical compositions of the invention contain a safe and effective amount (e.g., 0.001-99wt%, preferably 0.01-90wt%, more preferably 0.1-80 wt%) of the antibodies (or conjugates thereof) of the invention as described above, and a pharmaceutically acceptable carrier or excipient. Such vectors include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical formulation should be compatible with the mode of administration. The pharmaceutical compositions of the invention may be formulated as injectables, e.g. by conventional means using physiological saline or aqueous solutions containing glucose and other adjuvants. The pharmaceutical compositions, such as injections, solutions are preferably manufactured under sterile conditions. The amount of active ingredient administered is a therapeutically effective amount, for example, from about 10 micrograms per kilogram of body weight to about 50 milligrams per kilogram of body weight per day. In addition, the polypeptides of the invention may also be used with other therapeutic agents.
When a pharmaceutical composition is used, a safe and effective amount of the immunoconjugate is administered to the mammal, wherein the safe and effective amount is typically at least about 10 micrograms per kilogram of body weight, and in most cases no more than about 50 milligrams per kilogram of body weight, preferably the dose is from about 10 micrograms per kilogram of body weight to about 10 milligrams per kilogram of body weight. Of course, the particular dosage should also take into account factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled practitioner.
Detection method
The invention also relates to a method for detecting serum albumin. The method comprises the following steps: obtaining a cell and/or tissue sample; dissolving a sample in a medium; detecting the level of serum albumin in the solubilized sample.
In the detection method of the present invention, the sample used is not particularly limited, and a representative example is a cell-containing sample present in a cell preservation solution.
Kit for detecting a substance in a sample
The invention also provides a kit comprising an antibody (or fragment thereof) or assay plate of the invention, which in a preferred embodiment of the invention further comprises a container, instructions for use, buffers, and the like.
The invention also provides a detection kit for detecting serum albumin level, which comprises an antibody for recognizing serum albumin, a lysis medium for dissolving a sample, and a general reagent and a buffer solution required for detection, such as various buffers, detection marks, detection substrates and the like. The detection kit may be an in vitro diagnostic device.
Application of
As described above, the nano antibody of the invention has wide biological application value and clinical application value, and the application relates to the application of the antiserum albumin nano antibody in preparing long-acting protein medicines, thus providing a research and development basis for the development of the long-acting protein medicines.
The main advantages of the invention include:
(a) The nano antibody can be combined with serum albumin of human, mouse, rat and cynomolgus monkey under different pH conditions.
(b) The nano antibody can obviously prolong the half life of the protein drug, and provides a research and development basis for the development of long-acting protein drugs.
(c) The nano antibody is suitable for prokaryotic expression and eukaryotic expression, has the advantages of extremely high solubility, difficult aggregation, high temperature resistance, strong acid, strong alkali and other denaturation conditions, and is suitable for laboratory and industrial development.
(d) The protein medicine prepared by the nano antibody of the invention can not influence the targeting property and activity of the medicine.
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental procedure, which does not address the specific conditions in the examples below, is generally followed by routine conditions, such as, for example, sambrook et al, molecular cloning: conditions described in the laboratory Manual (New York: cold Spring Harbor Laboratory Press, 1989) or as recommended by the manufacturer. Percentages and parts are weight percentages and parts unless otherwise indicated.
Example 1: screening and expression of antiserum albumin nano antibody
Example 2: binding of anti-serum albumin nanobodies to albumin at different pH conditions
Diluting serum of mice, rats and cynomolgus monkey and human serum albumin with pH8.2 NaHCO3 to 10ug/mL, coating the solution on an enzyme-labeled plate, and standing at 4 ℃ overnight; PBST washes the ELISA plate, and 300uL of 1% skimmed milk is added into each hole to be sealed for 2 hours at room temperature; PBST washes the ELISA plate, adds 100uL of antibody to be tested diluted in gradient (each antibody is diluted with PBS solution with pH5.0 and pH7.4 respectively, 3-fold gradient dilution is started from 300 ug/mL), incubate for 1 hour at 37 ℃; the ELISA plate was washed with PBST, 100uL of diluted Goat pAb to Nanobody (HRP) (diluted 1:1000 in PBS) was added and incubated at 37℃for 1 hour; the enzyme-labeled plate is washed by PBST, 100uL of TMB color development liquid is added, the reaction is carried out for 5 minutes at room temperature in a dark place, 50uL of 2M sulfuric acid is added to stop the color development, and the absorption value is read at the wavelength of 450nm of the enzyme-labeled instrument. The results are shown in FIGS. 1A-1D: the four anti-serum albumin nano antibodies can be combined with serum albumin of human, mice, rats and cynomolgus monkeys simultaneously, and can be combined with serum albumin of various species under different pH conditions (pH 5.0 and pH 7.4). The numerical statistics are shown in Table 2.
TABLE 2 binding of anti-serum Albumin nanobodies to Albumin of different species
Example 3: humanization of anti-serum albumin nanobodies
The amino acid sequences of the 4 nano antibodies are placed in a structural database to search for homologous structures, and the antibody sequences are shown in Table 3.
TABLE 3 sequence numbering of anti-serum albumin nanobodies
Antibody numbering | Nb1-15 | Nb1-60 | Nb1-83 | Nb3-24 |
CDR1 | SEQ ID NO.1 | SEQ ID NO.10 | SEQ ID NO.19 | SEQ ID NO.28 |
CDR2 | SEQ ID NO.2 | SEQ ID NO.11 | SEQ ID NO.20 | SEQ ID NO.29 |
CDR3 | SEQ ID NO.3 | SEQ ID NO.12 | SEQ ID NO.21 | SEQ ID NO.30 |
FR1 | SEQ ID NO.4 | SEQ ID NO.13 | SEQ ID NO.22 | SEQ ID NO.31 |
FR2 | SEQ ID NO.5 | SEQ ID NO.14 | SEQ ID NO.23 | SEQ ID NO.32 |
FR3 | SEQ ID NO.6 | SEQ ID NO.15 | SEQ ID NO.24 | SEQ ID NO.33 |
FR4 | SEQ ID NO.7 | SEQ ID NO.16 | SEQ ID NO.25 | SEQ ID NO.34 |
Full-length amino acid sequence | SEQ ID NO.8 | SEQ ID NO.17 | SEQ ID NO.26 | SEQ ID NO.35 |
Full-length base sequence | SEQ ID NO.9 | SEQ ID NO.18 | SEQ ID NO.27 | SEQ ID NO.36 |
Comparing the structures with high sequence isogeny, finally selecting proteins including 3dwt according to the resolution of the crystal structure and the constructed evolutionary tree, carrying out multi-template homologous modeling of the target nano antibody sequence, and selecting the structure with the lowest molpdf according to the high-low ranking of the scoring function; and then calculating solvent accessibility of the residues by using the ProtSA server on the modeled optimal structure, and performing sequence alignment on the modeled optimal structure and DP-47 to replace the corresponding residues exposed to the solvent. Finally, a humanized anti-serum albumin nanobody is determined, and the humanized antibody sequence corresponds to the following table 4:
TABLE 4 humanized anti-serum Albumin nanobody sequence numbering
Example 4: construction and expression of HSA-IL4R trivalent nanobody
The IL4R nanobody is selected as a representative to construct a long-acting protein drug with the humanized albumin nanobody so as to verify the function of the humanized albumin nanobody for prolonging the in vivo half-life of the protein. The 4 candidate humanized albumin nanobodies are respectively connected in series with IL4R nanobodies (the sequences of the humanized albumin nanobodies are derived from patent CN 2019110547879) to form trivalent nanobodies, and the structural sequences of the trivalent nanobodies are shown in the following table 5:
TABLE 5 multivalent antibody structures and sequences
Antibody numbering | Structure of the | Amino acid sequence | Base sequence |
MY8154 | IL4R Nb103-Nb103-HSA HuNb1-15 | SEQ ID NO.61 | SEQ ID NO.62 |
MY8267 | IL4R Nb103-Nb103-HSA HuNb1-60 | SEQ ID NO.63 | SEQ ID NO.64 |
MY8162 | IL4R Nb103-Nb103-HSA HuNb1-83 | SEQ ID NO.65 | SEQ ID NO.66 |
MY8268 | IL4R Nb103-Nb103-HSA HuNb3-24 | SEQ ID NO.67 | SEQ ID NO.68 |
MY8171 | IL4R Nb103-Nb103 | SEQ ID NO.69 | SEQ ID NO.70 |
The multivalent antibody was expressed using pichia pastoris. Briefly, the expression method is as follows: (1) Constructing the bases of the nanometer antibody sequences shown in SEQ ID NO.62, SEQ ID NO.64, SEQ ID NO.66, SEQ ID NO.68 and SEQ ID NO.70 into a pPICZaA carrier; (2) Electrotransformation into X-33 competent cells after linearization with SacI restriction enzyme; (3) Electroblotted samples were each plated on YPD plate medium containing bleomycin resistance at different concentrations and incubated in a 30℃incubator for 3 days, see for specific embodiments pPICZaA vector instructions from Invitrogen; (4) After the monoclonal grows on the plate culture medium, selecting the monoclonal and placing the monoclonal in a BMGY culture medium, when the OD value of the BMGY culture medium reaches about 20, collecting thalli, replacing the thalli into the BMMY culture medium, and culturing at 28 ℃ and 250 rpm; (5) after every 24 hours 1% methanol was added to the final volume; continuously inducing for 5 days, and ending the culture; (6) The obtained supernatant was purified by cation chromatography to obtain the objective antibody.
The above expressed purified antibodies were subjected to different pH conditions to detect their binding to albumin of various genus. The detection method is the same as that of example 2, and the results are shown in fig. 2A to 2D: the humanized trivalent antibody fused with the human IL4R nanobody can still be combined with serum albumin of different species, and the combination activity of the humanized trivalent antibody is not changed depending on pH change. The numerical statistics are shown in Table 6.
TABLE 6 binding of humanized trivalent antibodies to serum Albumin of different species
Example 5: half-life of antiserum albumin nanobody in mouse
The multivalent antibody expressed by 100ug yeast cells is respectively injected into mice intravenously, and after administration, orbital blood is taken for 5min, 3h, 8h, 24h, 48h, 96h and 144h respectively, and plasma is separated after centrifugation. Wherein the blood collection time points after administration of the control antibody MY8171 are 5min, 15min, 30min, 1.5h and 3h. PK analysis was then performed using ELISA detection. Coating enzyme-labeled version with 1ug/mL hIL4R protein at 100 uL/well overnight; PBST plates were washed 5 times, and 300uL of 0.3% Casein was added and blocked at room temperature for 2 hours; PBST plates were washed 5 times and diluted serum samples were added to the corresponding wells and incubated for 1 hour at 37 ℃; PBST plates were washed 5 times and incubated at 37℃for 1 hour with the addition of coat 1 pAb to Nanobody-HRP (1:1000 dilution) at 100 uL/well; PBST plates were washed 5 times, added with TMB developing solution, left to stand at room temperature for developing for 5 minutes, and then added with 2M sulfuric acid to terminate the reaction, and the absorption value was read at a wavelength of 450nm by an ELISA reader. Converting the detection result according to a standard curve to obtain a time-drug concentration relation diagram, wherein the result is shown in fig. 3: the half-life of the divalent antibody MY8171 without albumin nanobody in the mouse is only about 1.86 hours, while the half-life of the trivalent antibody with antiserum albumin nanobody in the mouse is obviously prolonged (as shown in table 7), and the half-life of the trivalent antibody with antiserum albumin nanobody in the mouse can be prolonged by about 22 times at most.
TABLE 7 half-life of different antisera Albumin nanobodies in mice
Antibody numbering | MY8171 | MY8154 | MY8267 | MY8162 | MY8268 |
T 1/2 (hours) | 1.86 | 16.50 | 30.35 | 8.98 | 40.99 |
Example 6: half-life of antiserum albumin nanobody in rat body
The multivalent antibodies expressed by 400ug yeast cells are respectively injected into rats intravenously, and the orbital blood is respectively taken for 5min, 3h, 8h, 24h, 48h, 96h and 144h after administration, and the plasma is separated after centrifugation. Wherein the blood collection time points after administration of the control antibody MY8171 are 5min, 15min, 30min, 1.5h and 3h. PK analysis was then performed using ELISA detection. The detection method is the same as in example 5. Converting the detection result according to a standard curve to obtain a time-drug concentration relation diagram, wherein the result is shown in fig. 4: the half-life of the divalent antibody MY8171 without albumin nanobody in the rat is only about 0.82 hours, while the half-life of the trivalent antibody with antiserum albumin nanobody in the mouse is obviously prolonged (as shown in table 8), and the half-life of the trivalent antibody with antiserum albumin nanobody in the mouse can be prolonged by about 63 times at most.
TABLE 8 half-life of different antisera Albumin nanobodies in rats
Antibody numbering | MY8171 | MY8154 | MY8267 | MY8268 |
T 1/2 (hours) | 0.82 | 41.63 | 51.96 | 51.42 |
Example 7: half-life of antiserum albumin nano-antibody in cynomolgus monkey body
Two antibodies of MY8267 and MY8268 were respectively injected intravenously into the left anterior limb of a cynomolgus monkey at a dose of 2mg/kg, blood was taken from the right anterior limb 5min, 20min, 1h, 2h, 4h, 8h, 16h, 1day, 2day, 4day, 6day, 8day, 11day, 14day, 17day, 20day, 23day, 26day, 29day, 32day, 35day, respectively, and plasma was separated after centrifugation. PK analysis was then performed using ELISA detection. The detection method is the same as in example 5. Converting the detection result according to a standard curve to obtain a time-drug concentration relation diagram, wherein the result is shown in fig. 5: the half-life of the trivalent antibody with the anti-serum albumin nanobody in the cynomolgus monkey body can reach about 9-15 days (table 9).
TABLE 9 half-life of different antisera Albumin nanobodies in cynomolgus monkey
Antibody numbering | MY8267 | MY8268 |
T 1/2 (days) | 9.53 | 14.21 |
All documents mentioned in this application are incorporated by reference as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the claims appended hereto.
Claims (10)
1. An anti-serum albumin nanobody, wherein said nanobody is capable of specifically binding serum albumin and the VHH chain of said nanobody has complementarity determining region CDRs as follows:
CDR1 shown in SEQ ID NO. 28, CDR2 shown in SEQ ID NO. 29, and CDR3 shown in SEQ ID NO. 30.
2. The nanobody of claim 1, wherein the VHH chain of the nanobody further comprises a framework region FR selected from the group consisting of:
(1) FR1 shown in SEQ ID NO. 31, FR2 shown in SEQ ID NO. 32, FR3 shown in SEQ ID NO. 33 and FR4 shown in SEQ ID NO. 34; and
(2) FR1 shown in SEQ ID NO. 55, FR2 shown in SEQ ID NO. 56, FR3 shown in SEQ ID NO. 57 and FR4 shown in SEQ ID NO. 58.
3. The nanobody of claim 1, wherein the amino acid sequence of the VHH chain of the nanobody is selected from the group consisting of: SEQ ID NO. 35 and SEQ ID NO. 59.
4. An anti-serum albumin antibody comprising the VHH chain of the nanobody of claim 1.
5. A polynucleotide encoding a protein selected from the group consisting of: the nanobody of claim 1 or the antibody of claim 4.
6. The polynucleotide of claim 5, wherein the nucleotide sequence of said polynucleotide is selected from the group consisting of: SEQ ID NO. 36 and SEQ ID NO. 60.
7. An expression vector comprising the polynucleotide of claim 5.
8. A host cell comprising the expression vector of claim 7, or having integrated into its genome the polynucleotide of claim 5.
9. A method of producing an anti-serum albumin nanobody comprising the steps of:
(a) Culturing the host cell of claim 8 under conditions suitable for nanobody production, thereby obtaining a culture comprising anti-serum albumin nanobody;
(b) Isolating and/or recovering said anti-serum albumin nanobodies from said culture; and
(c) Optionally purifying and/or modifying the antisera albumin nanobody obtained in step (b).
10. A fusion protein, said fusion protein comprising:
(i) The nanobody of claim 1;
(ii) Optionally a polypeptide molecule or fragment having therapeutic functions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310346381.8A CN116284375A (en) | 2020-08-14 | 2020-08-14 | pH-independent long-acting type antiserum albumin nano antibody and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010820234.6A CN114075279B (en) | 2020-08-14 | 2020-08-14 | pH-independent long-acting type antiserum albumin nano antibody and application thereof |
CN202310346381.8A CN116284375A (en) | 2020-08-14 | 2020-08-14 | pH-independent long-acting type antiserum albumin nano antibody and application thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010820234.6A Division CN114075279B (en) | 2020-08-14 | 2020-08-14 | pH-independent long-acting type antiserum albumin nano antibody and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116284375A true CN116284375A (en) | 2023-06-23 |
Family
ID=80280119
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010820234.6A Active CN114075279B (en) | 2020-08-14 | 2020-08-14 | pH-independent long-acting type antiserum albumin nano antibody and application thereof |
CN202310346361.0A Pending CN116284374A (en) | 2020-08-14 | 2020-08-14 | pH-independent long-acting type antiserum albumin nano antibody and application thereof |
CN202310346308.0A Pending CN116284373A (en) | 2020-08-14 | 2020-08-14 | pH-independent long-acting type antiserum albumin nano antibody and application thereof |
CN202310346381.8A Pending CN116284375A (en) | 2020-08-14 | 2020-08-14 | pH-independent long-acting type antiserum albumin nano antibody and application thereof |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010820234.6A Active CN114075279B (en) | 2020-08-14 | 2020-08-14 | pH-independent long-acting type antiserum albumin nano antibody and application thereof |
CN202310346361.0A Pending CN116284374A (en) | 2020-08-14 | 2020-08-14 | pH-independent long-acting type antiserum albumin nano antibody and application thereof |
CN202310346308.0A Pending CN116284373A (en) | 2020-08-14 | 2020-08-14 | pH-independent long-acting type antiserum albumin nano antibody and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (4) | CN114075279B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114656557B (en) * | 2022-03-23 | 2023-05-12 | 南开大学 | Serum ferritin specific nano antibody and ELISA method thereof |
CN117088975B (en) * | 2022-05-11 | 2024-06-25 | 东莞市朋志生物科技有限公司 | Anti-albumin antibody, reagent and kit for detecting albumin |
CN117164708A (en) * | 2022-05-26 | 2023-12-05 | 上海洛启生物医药技术有限公司 | Long-acting IL5 nanobody and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2752426A1 (en) * | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
CN111138537B (en) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | Anti-human serum albumin antibody fragment, preparation method and application |
CN111138536B (en) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | Preparation and application of anti-human serum albumin single-domain antibody |
-
2020
- 2020-08-14 CN CN202010820234.6A patent/CN114075279B/en active Active
- 2020-08-14 CN CN202310346361.0A patent/CN116284374A/en active Pending
- 2020-08-14 CN CN202310346308.0A patent/CN116284373A/en active Pending
- 2020-08-14 CN CN202310346381.8A patent/CN116284375A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114075279B (en) | 2023-05-05 |
CN114075279A (en) | 2022-02-22 |
CN116284374A (en) | 2023-06-23 |
CN116284373A (en) | 2023-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110144009B (en) | CD47 single domain antibodies and uses thereof | |
US11466085B2 (en) | Anti-PD-L1 nanobody, coding sequence and use thereof | |
CN109096395B (en) | Blocking type CD47 nano antibody and application thereof | |
CN110452297B (en) | anti-VEGF single domain antibody and application thereof | |
KR20180069931A (en) | Anti-PD-L1 nano-antibodies and their applications | |
CN112500480B (en) | Nanobodies against novel coronaviruses and uses thereof | |
CN114075279B (en) | pH-independent long-acting type antiserum albumin nano antibody and application thereof | |
CN111518212B (en) | anti-Trop 2 nano antibody and application thereof | |
CN113214394B (en) | anti-IL 5 nano antibody and application thereof | |
CN114853888B (en) | anti-TSLP nanobody and application thereof | |
CN111718415A (en) | anti-TIGIT nano antibody and application thereof | |
CN114106190A (en) | anti-VEGF/PD-L1 bispecific antibody and application thereof | |
CN115124621B (en) | PD-L1 targeted nano antibody and preparation method and application thereof | |
CN114380907B (en) | Nanometer antibody targeting CMTM6, and preparation method and application thereof | |
CN117980341A (en) | Anti-TROP 2 single domain antibody and application thereof | |
WO2021047386A1 (en) | Nano-antibody targeting caix antigen and application thereof | |
CN115873113B (en) | CaSR-targeted nano antibody and preparation method and application thereof | |
WO2024099310A1 (en) | Anti-il-13 long-acting nanobody sequence and use thereof | |
CN116333121A (en) | Development of novel targeted CD33 single domain antibody | |
CN118139893A (en) | Anti-PTK 7 single domain antibody and application thereof | |
CN118324913A (en) | Anti-PD-L1 nano antibody and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |